Oral pharmaceutical composition for the treatment of albinism

A composition and albinism technology, applied in the field of medicine, can solve the problems of lack of effective treatment drugs for albinism, failure to find out, etc.

Inactive Publication Date: 2018-07-27
TAIZHOU POLYTECHNIC COLLEGE
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Photosensitizing drugs, hormones, etc. can also be used for treatment, but there is still no effective treatment for albinism
[0004] Domestic Tu Caixia et al. (Tu Caixia, Zhang Rongxin, Ma Jingxin, Liu Yaling, Liu Ying, Li Hong. Animal pigmentation effect of eclipta echinacea ethanol extract and its effect on melanogenesis of mouse B16 melanoma cells. Chinese Integrative Medicine and Western Medicine Skin Journal of Venereology. 2006,5 (1): 1-4) reported that Eclipta eclipta ethanol extract also has the effect of promoting melanin production and up-regulating tyrosinase activity, but failed to find out the effect of Eclipta eclipta ethanol extract promoting Melanogenesis, an active monomeric compound that upregulates tyrosinase activity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oral pharmaceutical composition for the treatment of albinism
  • Oral pharmaceutical composition for the treatment of albinism
  • Oral pharmaceutical composition for the treatment of albinism

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Example 1 Oral tablet for the treatment of albinism and its preparation

[0017] The oral tablet formulations used to treat albinism are as follows:

[0018]

[0019] Oral tablets for the treatment of albinism are prepared as follows:

[0020] 1) Take the prescription amount of wedelolactone and metformin hydrochloride and grind them separately, pass through an 80-mesh sieve, and mix to obtain raw material powder;

[0021] 2) Take the prescribed amount of starch and add water to prepare a starch slurry with a concentration of 5%;

[0022] 3) Add the raw material powder obtained in step 1) to the starch slurry obtained in step 2), then add the excipients in the prescription except hydroxypropyl methylcellulose and titanium dioxide, mix evenly, and press the tablet core;

[0023] 4) Add hydroxypropyl methylcellulose and titanium dioxide to ethanol to dissolve and disperse as a coating solution to coat the tablet cores in step 3).

Embodiment 2

[0024] Example 2 Anti-albinism pharmacodynamics research and safety research

[0025] 144 male albino rats, 28 weeks old, weighing 320-350 g, were randomly divided into 8 groups, 18 rats in each group. During the experiment, free access to food and water, 12 hours of light and dark cycle light.

[0026] Group A was given normal saline by intragastric administration;

[0027] Group B was given metformin hydrochloride aqueous solution by intragastric administration, and the dose of metformin hydrochloride was 10 mg / kg;

[0028] Group C was given wedelia lactone aqueous suspension by intragastric administration, and the dose of wedelia lactone was 90 mg / kg;

[0029] Group D was given metformin hydrochloride and wedelolactin aqueous suspension by intragastric administration, and the doses of metformin hydrochloride and wedelia lactone were 10 mg / kg and 50 mg / kg respectively;

[0030] Group E was intragastrically given metformin hydrochloride and wedelide aqueous suspension, the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
Login to view more

Abstract

The invention relates to the field of medicines, in particular to an oral medicine composition for treating albinism. The oral medicine composition comprises medically acceptable excipients and raw materials. The raw materials include, by weight, 5-9 parts of wedelolactone and 1 part of metformin hydrochloride. The oral medicine composition has the advantages that obvious albinism treatment effects cannot be realized by the metformin hydrochloride, but albinism improving effects of the wedelolactone can be obviously improved if the metformin hydrochloride and the wedelolactone are jointly orally administered.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to an oral pharmaceutical composition for treating albinism. Background technique [0002] Albinism is a hereditary leukoplakia disease caused by lack of melanin in the skin and accessory organs caused by tyrosinase deficiency or dysfunction. Affected individuals usually present with anopigmented retinas, pinkish irises and pupils, and photophobia. The skin, eyebrows, hair, and other body hair are white or yellowish-white. The disease is a familial hereditary disease, which is generally believed to be an autosomal recessive genetic disease, and often occurs in people who marry consanguineous relatives. However, there are also cases where two albinos are married and their offspring are normal, indicating that there are at least two different genetic types of albinism. [0003] The current treatment of albinism is mainly through physical methods to minimize the damage of ultravi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/37A61K31/155A61P17/00A61P27/02
CPCA61K31/155A61K31/37A61K2300/00
Inventor 郑涛吕志阳朱露莎
Owner TAIZHOU POLYTECHNIC COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap